



## **Collegium to Host Conference Call to Discuss Fourth Quarter 2017 Financial Results and Provide Corporate Update**

February 26, 2018

CANTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

### **Conference Call Information:**

To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 764-8078. An audio webcast will be accessible from the Investor Relations section of the Company's website: <http://www.collegiumpharma.com/>. An archived webcast will be available on the Company's website approximately two hours after the event.

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx<sup>®</sup> technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

### **About Xtampza ER**

Xtampza<sup>®</sup> ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

[adasalla@collegiumpharma.com](mailto:adasalla@collegiumpharma.com)



Source: Collegium Pharmaceutical, Inc.